chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
CHILDREN'S ADVIL ALLERGY SINUS (chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride) by GSK. Approved for these symptoms due to hay fever, other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose and 1 more indications. First approved in 2004.
Drug data last refreshed 6m ago · AI intelligence enriched 6m ago
Children's Advil Allergy Sinus is a fixed-dose oral suspension combining ibuprofen (NSAID), chlorpheniramine maleate (first-generation antihistamine), and pseudoephedrine hydrochloride (decongestant) for pediatric patients. It treats upper respiratory allergy symptoms including runny nose, itchy/watery eyes, sneezing, and throat itching associated with hay fever and environmental allergies. The combination addresses multiple symptom pathways: anti-inflammatory/analgesic, antihistaminic, and nasal decongestant effects.
Product approaching loss of exclusivity with moderate competitive pressure (30) indicates defensive market positioning and potential team consolidation in coming years.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CHILDREN'S ADVIL ALLERGY SINUS at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Children's Advil Allergy Sinus offers career opportunities in defensive brand management, generic transition strategy, and cost containment as the product approaches LOE. Roles focus on maximizing remaining exclusivity period and planning orderly post-LOE portfolio transition rather than growth initiatives.